Cure My Disease

Don't miss your cure!

 Log in / Sign up

New lens implants promise clear vision at all distances after cataract surgery

NCT ID NCT07161635

Disease control Sponsor: Alcon Research Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests two types of advanced lens implants (IOLs) for people having cataract surgery in both eyes. The lenses are designed to help see clearly at far, arm's length, and near distances. Researchers will check safety and how well the lenses work in 110 participants over time.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Clareon PanOptix Pro and Pro Toric trifocal intraocular lenses (IOLs)
What this could lead to
If successful, this study could confirm that these IOLs provide reliable vision at far, arm's length, and near after cataract surgery.
What could go wrong
This is a post-market study with no control group, so results may not prove superiority over other lenses. Risks include typical cataract surgery complications like infection or inflammation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

110 people

The number who actually took part.

Started

Oct 2025

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

22 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: * Subjects with cataracts in both eyes, planned for removal by routine surgery (phacoemulsification); * Subject must be able to understand and sign an approved informed consent form; * Subject is willing to complete all the required study visits for the duration of the study; * Other protocol-defined inclusion criteria may apply. Key Exclusion Criteria: * Ocular conditions as specified in the protocol; * Subjects who desire monovision correction; * Previous intraocular or corneal surgery; * Other protocol-defined exclusion criteria may apply.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Aphakia are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Aphakia cataract congenital primary aphakia presbyopia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Aphakia Presbyopia

Contacts and locations

Locations

  • Carolina Eyecare Physicians LLC

    Mt. Pleasant, South Carolina, 29464, United States

  • Houston Eye Associates

    Houston, Texas, 77008, United States

  • Moyes Eye Center

    Kansas City, Missouri, 64154, United States

  • The Eye Institute of Utah

    Salt Lake City, Utah, 84107, United States

  • Wolstan & Goldberg Eye Associates

    Torrance, California, 90505, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.